Chlorphenoxamine

Identification

Name
Chlorphenoxamine
Accession Number
DB09007
Type
Small Molecule
Groups
Withdrawn
Description

Chlorphenoxamine (Phenoxene) is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Chlorphenoxamine hydrochloride5I159322PY562-09-4PAQUKACYLLABHB-UHFFFAOYSA-N
International/Other Brands
Sistral (I.E. Ulagay) / Systral (Altian)
Categories
UNII
3UVD77BP8R
CAS number
77-38-3
Weight
Average: 303.826
Monoisotopic: 303.138992038
Chemical Formula
C18H22ClNO
InChI Key
KKHPNPMTPORSQE-UHFFFAOYSA-N
InChI
InChI=1S/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3
IUPAC Name
{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}dimethylamine
SMILES
CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Chlorphenoxamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorphenoxamine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Experimental, Illicit
AclidiniumAclidinium may increase the anticholinergic activities of Chlorphenoxamine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Ambenonium.Approved
AmphetamineAmphetamine may decrease the sedative activities of Chlorphenoxamine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Chlorphenoxamine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Chlorphenoxamine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Chlorphenoxamine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Chlorphenoxamine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Chlorphenoxamine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Chlorphenoxamine.Approved, Illicit
Benzylpenicilloyl PolylysineChlorphenoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorphenoxamine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Chlorphenoxamine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Chlorphenoxamine.Experimental
Botulinum Toxin Type AChlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BChlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Chlorphenoxamine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Chlorphenoxamine.Illicit, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Chlorphenoxamine.Approved
CimetropiumChlorphenoxamine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Chlorphenoxamine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Chlorphenoxamine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Chlorphenoxamine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenoxamine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Chlorphenoxamine.Withdrawn
DextroamphetamineDextroamphetamine may decrease the sedative activities of Chlorphenoxamine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Chlorphenoxamine.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Chlorphenoxamine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with DPDPE.Investigational
DronabinolChlorphenoxamine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Edrophonium.Approved
EluxadolineChlorphenoxamine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Chlorphenoxamine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Chlorphenoxamine.Approved
GalantamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Chlorphenoxamine.Approved
GepefrineGepefrine may decrease the sedative activities of Chlorphenoxamine.Experimental
Ginkgo bilobaThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glucagon recombinant.Approved
GlycopyrroniumChlorphenoxamine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Chlorphenoxamine.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chlorphenoxamine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Chlorphenoxamine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Chlorphenoxamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Chlorphenoxamine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Chlorphenoxamine.Approved
IpidacrineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Chlorphenoxamine.Approved
IsoflurophateThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Chlorphenoxamine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levorphanol.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Chlorphenoxamine.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorphenoxamine.Approved
MefloquineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Memantine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Chlorphenoxamine.Investigational
MephentermineMephentermine may decrease the sedative activities of Chlorphenoxamine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Chlorphenoxamine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Chlorphenoxamine.Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Chlorphenoxamine.Experimental
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Chlorphenoxamine.Approved
Methyl salicylateThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine.Approved
MianserinMianserin may increase the anticholinergic activities of Chlorphenoxamine.Approved
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Chlorphenoxamine.Experimental, Illicit
MinaprineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Mirabegron.Approved
MMDAMMDA may decrease the sedative activities of Chlorphenoxamine.Experimental, Illicit
MorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Morphine.Approved, Investigational
NabiloneChlorphenoxamine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorphenoxamine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Chlorphenoxamine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Chlorphenoxamine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Chlorphenoxamine.Approved
ParaoxonThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Chlorphenoxamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Chlorphenoxamine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Phenoperidine.Experimental
PhenterminePhentermine may decrease the sedative activities of Chlorphenoxamine.Approved, Illicit
PhysostigmineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Chlorphenoxamine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Chlorphenoxamine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Chlorphenoxamine.Approved
Potassium ChlorideChlorphenoxamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Chlorphenoxamine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Chlorphenoxamine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Chlorphenoxamine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Propiverine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Chlorphenoxamine.Approved
PyridostigmineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Chlorphenoxamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Chlorphenoxamine.Approved
RamosetronChlorphenoxamine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Remifentanil.Approved
RitobegronRitobegron may decrease the sedative activities of Chlorphenoxamine.Investigational
RivastigmineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenoxamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Chlorphenoxamine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Chlorphenoxamine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Chlorphenoxamine.Approved
TacrineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tilidine.Experimental
TiotropiumChlorphenoxamine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Chlorphenoxamine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlorphenoxamine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Chlorphenoxamine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Chlorphenoxamine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Chlorphenoxamine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Chlorphenoxamine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Chlorphenoxamine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Chlorphenoxamine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Chlorphenoxamine.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,785,202.

General References
Not Available
External Links
KEGG Drug
D07198
ChemSpider
6230
ChEBI
135288
ChEMBL
CHEMBL2110774
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorphenoxamine
ATC Codes
R06AA06 — ChlorphenoxamineR06AA56 — Chlorphenoxamine, combinationsD04AA34 — Chlorphenoxamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)128U.S. Patent 2,785,202.
Predicted Properties
PropertyValueSource
Water Solubility0.00582 mg/mLALOGPS
logP4.45ALOGPS
logP4.4ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity89.57 m3·mol-1ChemAxon
Polarizability34.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Benzylethers / Chlorobenzenes / Aryl chlorides / Trialkylamines / Dialkyl ethers / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Diphenylmethane / Benzylether / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Tertiary aliphatic amine / Tertiary amine / Ether / Dialkyl ether
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 19, 2014 18:14 / Updated on October 02, 2017 06:12